atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
Posted:
Atai Life Sciences a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. Read more here.
Schizophrenia is a psychiatric disorder characterized by altered thinking and emotional patterns, hallucinations, false or irrational beliefs (i.e., delusions), cognitive deficits, and disorganized speech.
Bipolar disorder BD, on the other hand, is marked by extreme mood swings, ranging between periods of…
New joint research program combines UCSF’s advanced clinical and research teams with GE HealthCare’s technical and engineering expertise to develop solutions that directly impact patient care.
Read full article here.
Attendees
Sponsors and Exhibitors
Contact us